Hans Wildiers

46PUBLICATIONS
350CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Aug 09, 2026
Determinants of Interest-Holder Perspectives Toward Post-Mortem Tissue Donation in Oncology: A Systematic Review.

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Jan 08, 2026
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Komal Jhaveri, Sherene Loi, Erika Hamilton

|Dec 25, 2025
Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue.

Kristien Borremans, Anirudh Pabba, Gitte Zels

|Dec 02, 2025
ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer.

François Richard, Marion Maetens, Karen Van Baelen

|Jun 13, 2025
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

Karen Van Baelen, Ha-Linh Nguyen, François Richard

Pageof 8

Frequent Collaborators

11 joint publications

Giuseppe Floris

10 joint publications

Patrick Neven

10 joint publications

Kevin Punie

10 joint publications

François Richard